Signs point to 'blockbuster' 2025 for M&A
“All signs are pointing to 2025 being a very strong year for M&A, potentially a blockbuster year,” he said. And recent ...
Why I'm Buying Blue Owl Capital Corp. III Over Blue Owl Capital Corp. In This Merger Arbitrage Opportunity
A dovish rates environment can put pressure on net investment income for the OBDC + OBDE portfolio. Read why there may be a ...
bovnews6d
A Bold Move in Biotech: NLS Pharmaceutics (NLSP) Sets the Stage for Major Change
The merger is seen as a way to diversify and strengthen NLS’s pipeline, incorporating Kadimastem’s innovative technologies into the portfolio. It also opens the door for Kadimastem to become a ...
BroadwayWorld6d
Raleigh Area Children's Theatre Will Merge With Theatre Raleig
Raleigh Area Children's Theatre will merge with Theatre Raleigh, the region's professional, nonprofit theatre company renown ...
TMCnet6d
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...